The report provides comprehensive information on the therapeutics under development by 4SC AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/619236-4sc-ag-product-pipeline-review-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of 4SC AG
- The report provides overview of 4SC AG including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses 4SC AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features 4SC AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate 4SC AG’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for 4SC AG
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 4SC AG’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
4SC AG Snapshot 5
4SC AG Overview 5
Key Information 5
Key Facts 5
4SC AG - Research and Development Overview 6
Key Therapeutic Areas 6
4SC AG - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
4SC AG - Pipeline Products Glance 13
4SC AG - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
4SC AG - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
4SC AG - Drug Profiles 17
resminostat 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
vidofludimus 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
4SC-202 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
4SC-205 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecule for Malaria 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecules for Neurological Disorders 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Inhibit Bromodomain for Cancer 33
Product Description 33
Mechanism of Action 33
Contact Info:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
No comments:
Post a Comment